Gilead Breaks Ground on New US Manufacturing Hub

It is part of Gilead’s planned $32 billion investment in US innovation through 2030. This investment is projected to generate more than $43 billion in economic value nationwide, strengthening America’s biopharmaceutical leadership while creating high-quality jobs, driving research, and fostering domestic manufacturing.

“This new facility is part of our vision for delivering next-generation therapies and a cornerstone of Gilead’s $32 billion investment commitment in the United States,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences. “We have multiple construction projects underway, all of which will generate thousands of American jobs and help to drive US leadership in global biopharma innovation.”

The five-story, 180,000-square-foot facility will serve as a hub for innovation and collaboration across technical development and manufacturing teams. Designed with flexible pilot lab space and advanced digital infrastructure, the NTDC will accelerate technology transfer and support the advancement of next-generation biologics across Gilead’s pipeline. It will feature digitally enabled systems, autonomous robotics, and real-time digital monitoring, making it one of the most AI-enabled centers in the biopharma industry.

The new facility will strengthen Gilead’s biologics capacity and capabilities, a central pillar of the company’s growth strategy. This investment builds on Gilead’s broader US efforts to expand research and manufacturing, create more than 3,000 direct and indirect high-quality jobs, and advance equitable access to healthcare nationwide.

This groundbreaking is part of a broader expansion at Gilead’s Foster City headquarters. In addition to the NTDC, the company is currently developing two other state-of-the-art facilities: a new research building designed to accelerate scientific discovery, already under construction, and a biologics manufacturing facility that will expand domestic production capacity. These current investments further build on Gilead’s strong history of US investment, with more than $15 billion over the last decade, and reinforce the company’s role as a major contributor to the US biopharmaceutical industry and a vital partner in driving scientific innovation and solutions for patients. Together, these investments form an integrated innovation ecosystem designed to accelerate discovery, streamline manufacturing, and reinforce Gilead’s role as a US-based biopharma leader in improving human health globally.